+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skeletal Dysplasia Market Size, Share & Trends Analysis Report by Type (Achondroplasia, X-linked Hypophosphatemia, Hypophosphatasia), Treatment, Symptom, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 90 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024660
Description Jump to:
The global skeletal dysplasia market size is expected to reach USD 3.85 billion by 2030, registering a CAGR of 2.0% from 2025 to 2030. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.

Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.

Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.

The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals’ Crysvita and Alexion Pharmaceuticals’ Strensiq, respectively. Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.

Skeletal Dysplasia Market Report Highlights

  • Hypophosphatasia (HPP) dominated the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the increasing awareness and improved diagnostic capabilities, leading to more frequent diagnoses of this rare genetic disorder.
  • Medications led the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the advancements in drug development and increased awareness of skeletal dysplasias.
  • Skeletal deformities, including parathyroid disorders, growth hormone therapies, and spinal and limb osteotomies, dominated the market and accounted for the largest revenue share of 20.9% in 2024.
  • Europe skeletal dysplasia market dominated the global market and accounted for the largest revenue share of 39.4% in 2024 attributed to heightened awareness and improved diagnostic capabilities.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Skeletal Dysplasia market include:

  • BioMarin
  • Amgen Inc.
  • Merck KGaA
  • Regeneron
  • Alexion Pharmaceuticals, Inc.
  • Clementia (Ipsen Group).
  • AstraZeneca plc.
  • Biomarin Pharmaceuticals Inc.
  • Cipla Ltd,
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disorder Type
1.2.2. Treatment
1.2.3. Symptoms
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Skeletal Dysplasia Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
Chapter 4. Skeletal Dysplasia Market: Disorder Type Business Analysis
4.1. Disorder Type Market Share, 2024 & 2030
4.2. Disorder Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Disorder Type, 2018 to 2030 (USD Million)
4.4. X-linked Hypophosphatemia (XLH)
4.4.1. X-linked Hypophosphatemia (XLH) Market, 2018 - 2030 (USD Million)
4.5. Hypophosphatasia (HPP)
4.5.1. Hypophosphatasia (HPP) Market, 2018 - 2030 (USD Million)
4.6. Achondroplasia
4.6.1. Achondroplasia Market, 2018 - 2030 (USD Million)
4.7. Fibrodysplasia Ossificans Progressive (FOP)
4.7.1. Fibrodysplasia Ossificans Progressive (FOP) Market, 2018 - 2030 (USD Million)
4.8. Multiple Osteochondromas (MO)
4.8.1. Multiple Osteochondromas (MO) Market, 2018 - 2030 (USD Million)
Chapter 5. Skeletal Dysplasia Market: Treatment Business Analysis
5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Medication
5.4.1. Medication Market, 2018 - 2030 (USD Million)
5.5. Surgery
5.5.1. Surgery Market, 2018 - 2030 (USD Million)
Chapter 6. Skeletal Dysplasia Market: Symptoms Business Analysis
6.1. Symptoms Market Share, 2024 & 2030
6.2. Symptoms Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Symptoms, 2018 to 2030 (USD Million)
6.4. Skeletal Deformities
6.4.1. Skeletal Deformities Market, 2018 - 2030 (USD Million)
6.5. Dental Deformities
6.5.1. Dental Deformities Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Skeletal Dysplasia Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Skeletal Dysplasia Market Estimates and Forecastsasts, 2018 - 2030 (USD Million)
7.5.10. Russia
7.5.10.1. Key Country Dynamics
7.5.10.2. Regulatory Framework
7.5.10.3. Competitive Insights
7.5.10.4. Russia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.7. Hong Kong
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Hong Kong Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.8. Thailand
7.6.8.1. Key Country Dynamics
7.6.8.2. Regulatory Framework
7.6.8.3. Competitive Insights
7.6.8.4. Thailand Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. BioMarin
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Amgen Inc.
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Merck KGaA
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Regeneron
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Alexion Pharmaceuticals, Inc.
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Clementia (Ipsen Group).
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. AstraZeneca plc.
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Biomarin Pharmaceuticals Inc.
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Cipla Ltd.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Eli Lilly and Company
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. F. Hoffmann-La Roche AG.
8.5.11.1. Company Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Pfizer, Inc.
8.5.12.1. Company Overview
8.5.12.2. Financial Performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic Initiatives
8.5.13. Teva Pharmaceutical Industries Ltd.
8.5.13.1. Company Overview
8.5.13.2. Financial Performance
8.5.13.3. Product Benchmarking
8.5.13.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Skeletal Dysplasia Market, by Region, 2018 - 2030 (USD Million)
Table 4 Global Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 5 Global Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 6 Global Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 7 North America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
Table 8 North America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 9 North America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 10 North America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 11 U.S Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 12 U.S Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 13 U.S Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 14 Canada Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 15 Canada Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 16 Canada Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 17 Mexico Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 18 Mexico Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 19 Mexico Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 20 Europe Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
Table 21 Europe Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 22 Europe Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 23 Europe Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 24 UK Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 25 UK Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 26 UK Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 27 Germany Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 28 Germany Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 29 Germany Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 30 France Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 31 France Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 32 France Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 33 Italy Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 34 Italy Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 35 Italy Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 36 Spain Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 37 Spain Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 38 Spain Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 39 Norway Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 40 Norway Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 41 Norway Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 42 Denmark Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 43 Denmark Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 44 Denmark Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 45 Sweden Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 46 Sweden Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 47 Sweden Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 52 Japan Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 53 Japan Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 54 Japan Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 55 China Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 56 China Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 57 China Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 58 India Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 59 India Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 60 India Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 61 Australia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 62 Australia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 63 Australia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 64 South Korea Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 65 South Korea Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 66 South Korea Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 67 Thailand Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 68 Thailand Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 69 Thailand Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 70 Latin America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
Table 71 Latin America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 72 Latin America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 73 Latin America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 74 Brazil Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 75 Brazil Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 76 Brazil Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 77 Argentina Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 78 Argentina Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 79 Argentina Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 84 South Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 85 South Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 86 South Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 90 UAE Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 91 UAE Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 92 UAE Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
Table 93 Kuwait Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
Table 94 Kuwait Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
Table 95 Kuwait Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Skeletal Dysplasia market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Segment outlook
Fig. 10 Segment outlook
Fig. 11 Competitive landscape
Fig. 12 Skeletal dysplasia market dynamics
Fig. 13 Skeletal dysplasia market: Porter’s five forces analysis
Fig. 14 Skeletal dysplasia market: PESTLE analysis
Fig. 15 Skeletal dysplasia market: Disorder Type segment dashboard
Fig. 16 Skeletal dysplasia market: Disorder Type market share analysis, 2024 & 2030
Fig. 17 X-linked hypophosphatemia (XLH) market, 2018 - 2030 (USD Million)
Fig. 18 Hypophosphatasia (HPP) market, 2018 - 2030 (USD Million)
Fig. 19 Achondroplasia market, 2018 - 2030 (USD Million)
Fig. 20 Fibrodysplasia ossificans progressive (FOP) market, 2018 - 2030 (USD Million)
Fig. 21 Multiple osteochondromas (MO) market, 2018 - 2030 (USD Million)
Fig. 22 Skeletal dysplasia market: Treatment segment dashboard
Fig. 23 Skeletal dysplasia market: Treatment market share analysis, 2024 & 2030
Fig. 24 Medication market, 2018 - 2030 (USD Million)
Fig. 25 Surgery market, 2018 - 2030 (USD Million)
Fig. 26 Skeletal dysplasia market: Symptoms segment dashboard
Fig. 27 Skeletal dysplasia market: Symptoms market share analysis, 2024 & 2030
Fig. 28 Skeletal deformities market, 2018 - 2030 (USD Million)
Fig. 29 Dental deformities laboratories market, 2018 - 2030 (USD Million)
Fig. 30 Others market, 2018 - 2030 (USD Million)
Fig. 31 Skeletal dysplasia market revenue, by region
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 Regional marketplace: Key takeaways
Fig. 34 North America skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 35 U.S. country dynamics
Fig. 36 U.S. skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 37 Canada country dynamics
Fig. 38 Canada skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 39 Mexico country dynamics
Fig. 40 Mexico skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 41 Europe skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 42 UK country dynamics
Fig. 43 UK skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 44 Germany country dynamics
Fig. 45 Germany skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 46 France country dynamics
Fig. 47 France skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 48 Italy country dynamics
Fig. 49 Italy skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 50 Spain country dynamics
Fig. 51 Spain skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 52 Norway country dynamics
Fig. 53 Norway skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 54 Sweden country dynamics
Fig. 55 Sweden skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 56 Denmark country dynamics
Fig. 57 Denmark skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 58 Asia Pacific skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 59 Japan country dynamics
Fig. 60 Japan skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 61 China country dynamics
Fig. 62 China skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 63 India country dynamics
Fig. 64 India skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 65 Australia country dynamics
Fig. 66 Australia skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 67 South Korea country dynamics
Fig. 68 South Korea skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 69 Thailand country dynamics
Fig. 70 Thailand skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 71 Latin skeletal dysplasia Dysplasia market, 2018 - 2030 (USD Million)
Fig. 72 Brazil country dynamics
Fig. 73 Brazil skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 74 Argentina country dynamics
Fig. 75 Argentina skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 76 MEA Skeletal Dysplasia market, 2018 - 2030 (USD Million)
Fig. 77 South Africa country dynamics
Fig. 78 South Africa skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 79 Saudi Arabia country dynamics
Fig. 80 Saudi Arabia skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 81 UAE country dynamics
Fig. 82 UAE skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 83 Kuwait Key country dynamics
Fig. 84 Kuwait skeletal dysplasia market, 2018 - 2030 (USD Million)
Fig. 85 Company categorization
Fig. 86 Company market position analysis
Fig. 87 Strategic framework

Companies Mentioned

  • BioMarin
  • Amgen Inc.
  • Merck KGaA
  • Regeneron
  • Alexion Pharmaceuticals, Inc.
  • Clementia (Ipsen Group).
  • AstraZeneca plc.
  • Biomarin Pharmaceuticals Inc.
  • Cipla Ltd,
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages90
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.85 Billion
Compound Annual Growth Rate2.0%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Skeletal Dysplasia Market by Type, Treatment, End User - Global Forecast 2025-2030 - Product Image

Skeletal Dysplasia Market by Type, Treatment, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Skeletal Dysplasia Market - Product Image

Skeletal Dysplasia Market

  • Report
  • 200 Pages
  • Global
From
Skeletal Dysplasia Market - Forecasts from 2024 to 2029 - Product Image

Skeletal Dysplasia Market - Forecasts from 2024 to 2029

  • Report
  • 149 Pages
  • Global
From
Achondroplasia - Pipeline Insight, 2024 - Product Image

Achondroplasia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Achondroplasia - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Achondroplasia - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.